ALK Abello's phase 3 trial in China showed that ACARIZAX®, a sublingual immunotherapy tablet for house dust mite allergy, is safe and effective after 24-28 weeks of treatment. The trial met its primary goal with significant symptom improvement and good tolerance among participants aged 12-65. These results align with previous global studies and support ALK's plan to file for regulatory approval in China in the first half of 2027, aiming to address the large under-treated allergy population there.
The phase 3 trial results for ACARIZAX® in China provide context for readers interested in health-sector developments. For readers following health stocks on Pluang as of Oct 19, 2026 20:02 WIB: out of 150 priced US health-sector stocks, 62 rose and 66 fell. Sanofi SA (SNY) traded at USD 39.90 with a 1-day change of -1.75% and a typical hold time of 94 days, contrasting with Summit Therapeutics Inc (SMMT) at USD 14.83 gaining 1.37% and held typically for 17 days, while Bristol-Myers Squibb Co (BMY) was priced at USD 58.95, down 1.34%, with a typical hold time of 92 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
